Sign in Subscribe

Alex Chompff

Risk-adapted FIT screening intervals may personalize colorectal cancer screening

Skip to content The CRC Digest ▪ SCREENING Risk-adapted FIT screening intervals may personalize colorectal cancer screening A modeling study based on the BLITZ cohort suggests that screening intervals for fecal immunochemical tests could be tailored based on quantitative hemoglobin levels in initially negative tests, stratifying participants into low, medium, and

Antibody-drug conjugate targeting c-MET shows 15.6% response rate in heavily pretreated mCRC

Skip to content The CRC Digest ▸ TREATMENT Antibody-drug conjugate targeting c-MET shows 15.6% response rate in heavily pretreated mCRC Telisotuzumab adizutecan, which delivers a topoisomerase inhibitor to c-MET-expressing tumor cells, achieved an objective response rate of 15.6% in 122 heavily pretreated metastatic colorectal cancer patients in a phase

Sotorasib plus panitumumab and FOLFIRI shows activity in KRAS G12C-mutated metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Sotorasib plus panitumumab and FOLFIRI shows activity in KRAS G12C-mutated metastatic CRC In the phase Ib CodeBreaK 101 trial, the triple combination of sotorasib (a KRAS G12C inhibitor), panitumumab, and FOLFIRI chemotherapy was tested in previously treated patients with KRAS G12C-mutated metastatic

CRC Research Update — August 19, 2026

Today's colorectal cancer research highlights

KRAS G12C Inhibitors in Metastatic CRC: Combination Strategies Reviewed

Skip to content The CRC Digest KRAS G12C Inhibitors in Metastatic CRC: Combination Strategies Reviewed A review article discusses how KRAS G12C mutations account for 3% to 4% of metastatic colorectal cancer cases and explains why combined KRAS G12C and EGFR inhibition may be more effective than monotherapy. (Journal of

Watch-and-Wait After Neoadjuvant Anti-PD-1 in dMMR/MSI-H CRC

Skip to content The CRC Digest Watch-and-Wait After Neoadjuvant Anti-PD-1 in dMMR/MSI-H CRC A multicenter real-world study from four Chinese hospitals evaluated long-term outcomes of a watch-and-wait strategy in stage II/III dMMR/MSI-H colorectal cancer patients who achieved endoscopic complete response after neoadjuvant anti-PD-1 monotherapy. (Frontiers in Immunology)

Traditional Risk Factors Not Linked to Early-Onset CRC Rise

Skip to content The CRC Digest Traditional Risk Factors Not Linked to Early-Onset CRC Rise A national cohort study using the All of Us Research Program found no significant association between traditional environmental risk factors or established genetic variants and the rising incidence of colorectal cancer in adults under age

FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRC A multicenter trial tested modified FOLFOXIRI combined with panitumumab every two weeks in patients with left-sided, RAS wild-type metastatic colorectal cancer. (The Oncologist) This content is informational only and does not

Follow-Up Colonoscopy Completion After Positive Stool DNA Test in Community Practice

Skip to content The CRC Digest ▪ SCREENING Follow-Up Colonoscopy Completion After Positive Stool DNA Test in Community Practice In a real-world study of patients with positive multi-target stool DNA tests, researchers evaluated follow-up colonoscopy completion rates and advanced neoplasia findings within 365 days. (Current Medical Research and Opinion) This content

WNT Pathway Activation Drives Immune Evasion in BRAF-Mutant Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH WNT Pathway Activation Drives Immune Evasion in BRAF-Mutant Colorectal Cancer Researchers using mouse models and organoids found that WNT pathway activation promotes malignant transformation and immune evasion in microsatellite-stable BRAF-mutant colorectal cancer. (Gastroenterology) This content is informational only and does not constitute medical